Skip to main content
VMDViemed Healthcare, Inc.Sell5.3·$12.02+2.39%
Open full analysis

Viemed Healthcare, Inc. (VMD) Stock Analysis

SellVALUE-TRAP 2/5High Confidence

Healthcare · Medical Devices

Sell if holding. Analyst target reached at $12.02 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away).

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary... Read more

$12.02-1.7% A.UpsideScore 5.3/10#36 of 64 Medical Devices
QualityF-score7 / 9FCF yield6.14%
Stop $11.22Target $11.82(resistance)A.R:R -1.5:1
Analyst target$11.00-8.5%1 analysts
Range unavailable (1 analysts)

Sell if holding. Analyst target reached at $12.02 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, high confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 5, 202632d to earnings· next earnings call

Thesis

Rewards
Positive momentum
Risks
Analyst target reached - limited upside remaining
Near 52-week high (0.4% away)
Leverage penalty (D/E 8.5): -1.5

Key Metrics

P/E (TTM)32.5
P/E (Fwd)30.1
Mkt Cap$461M
EV/EBITDA8.5
Profit Mgn5.2%
ROE10.9%
Rev Growth27.5%
Beta1.10
DividendNone
Rating analysts6

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

P/C0.13bullish
IV120%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
0.2
Bollinger
0.6
52w Position
9.9
GatesA.R:R -1.5=NEGATIVEMomentum 7.1>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 32d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
83 · Overbought
20D MA 50D MA 200D MAGOLDEN CROSSSupport $9.57Resistance $12.06

Price Targets

$11
$12
A.Upside-1.7%
A.R:R-1.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-22.2% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-05 (32d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is VMD stock a buy right now?

Sell if holding. Analyst target reached at $12.02 — A.R:R is negative (-1.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.22. Score 5.3/10, high confidence.

What is the VMD stock price target?

Take-profit target: $11.82 (-1.7% upside). Prior stop was $11.22. Stop-loss: $11.22.

What are the risks of investing in VMD?

Analyst target reached - limited upside remaining; Near 52-week high (0.4% away); Leverage penalty (D/E 8.5): -1.5.

Is VMD overvalued or undervalued?

Viemed Healthcare, Inc. trades at a P/E of 32.5 (forward 30.1). TrendMatrix value score: 4.9/10. Verdict: Sell.

What do analysts say about VMD?

6 analysts cover VMD with a consensus score of 4.0/5. Average price target: $11.

What does Viemed Healthcare, Inc. do?Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory...

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

Related stocks: DCTH (Delcath Systems, Inc.) · BWAY (Brainsway Ltd.) · TCMD (Tactile Systems Technology, Inc) · ATEC (Alphatec Holdings, Inc.) · MOBI (Mobia Medical, Inc.)
Home Stocks VMD

Latest news

No recent news